Methyl-tert.-butyl-thiophosphinsaeure-O-methylester | 27549-50-4

• 分子结构分类: 有机化合物 - 有机磷化合物 - 有机硫代磷化合物
• 英文名称: Methyl-tert.-butyl-thiophosphinsaeure-O-methylester
• 英文别名: Tert-butyl-methoxy-methyl-sulfanylidene-lambda5-phosphane；tert-butyl-methoxy-methyl-sulfanylidene-λ5-phosphane
• CAS: 27549-50-4
• 化学式: C₆H₁₅OPS
• 分子量: 166.224
• InChiKey: OYKYNRXELQWDBU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  41.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  Brom-tert-butyl-methyl-thiophosphinoxid 、 sodium methylate 以 乙醚 为溶剂， 生成 Methyl-tert.-butyl-thiophosphinsaeure-O-methylester
  参考文献：
  名称：

  Kuchen,W.; Haegele,G., Chemische Berichte, 1970, vol. 103, p. 2274 - 2280

  摘要：

  DOI：

文献信息

• Beta-D-2'-DEOXY-2'-alpha-FLUORO-2'-beta-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
  申请人：Atea Pharmaceuticals, Inc.

  公开号：US20160257706A1

  公开（公告）日：2016-09-08

  A compound of the structure: or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to an HCV virus or other disorders more fully described herein.

  一种结构的化合物： 或其药用可接受的盐或组合物，用于治疗感染或暴露于HCV病毒或其他在本文中更详细描述的疾病的宿主。
• β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
  申请人：Atea Pharmaceuticals, Inc.

  公开号：US10000523B2

  公开（公告）日：2018-06-19

  A compound of the structure: or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to an HCV virus or other disorders more fully described herein.

  结构的化合物： 或其药学上可接受的盐或组合物，用于治疗感染或暴露于 HCV 病毒的宿主或本文更全面描述的其他疾病。
• β-D-2′-deoxy-2′-α-fluoro-2′β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
  申请人：Atea Pharmaceuticals, Inc.

  公开号：US10005811B2

  公开（公告）日：2018-06-26

  A compound of the structure: or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to an HCV virus or other disorders more fully described herein.

  结构的化合物： 或其药学上可接受的盐或组合物，用于治疗感染或暴露于 HCV 病毒的宿主或本文更全面描述的其他疾病。
• BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
  申请人：Atea Pharmaceuticals, Inc.

  公开号：US20180030082A1

  公开（公告）日：2018-02-01

  A compound of the structure: or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to an HCV virus or other disorders more fully described herein.
• BETA-D-2'-DEOXY-2'-SUBSTITUTED-4'-SUBSTITUTED-2-SUBSTITUTED-N6-SUBSTITUTED-6-AMINOPURINENUCLEOTIDES FOR THE TREATMENT OF PARAMYXOVIRUS AND ORTHOMYXOVIRUS INFECTIONS
  申请人：Atea Pharmaceuticals, Inc.

  公开号：US20180009836A1

  公开（公告）日：2018-01-11

  A compound or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to a virus of the Paramyxoviridae or Orthomyxoviridae family, or other disorders, in particular respiratory syncytial virus, more fully described herein.